Literature DB >> 10873113

The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines.

L D Ke1, Y X Shi, S A Im, X Chen, W K Yung.   

Abstract

Tumor growth is partially dependent on angiogenesis, a process that relies on angiogenic factors. Tumorigenicity of cancer cells is thought to be associated with the production of various angiogenic factors that stimulate or inhibit the rate of endothelial cell migration and proliferation. However, the relative importance of specific individual factors originally studied in cancer cell lines has yet to be determined in vivo. In this study, we examined seven human glioma cell lines for dynamic changes of two major angiogenic factors, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), and for doubling time and tumorigenicity in nude mice. Various correlation studies demonstrated that in these glioma cell lines, VEGF expression correlated well with RBC density in tumor sections (r2 = 0.804) and with average tumor weight (r2 = 0.987). In contrast, bFGF expression in the observed glioma cell lines did not correlate with tumorigenicity (r2 = 0.001) or with VEGF expression (r2 = 0.255). Furthermore, there was no correlation between doubling time and tumorigenicity in these cell lines (r2 = 0.160). Taken together, these results suggest that VEGF plays a major role in glioma formation and that down-regulation of VEGF, rather than bFGF, would be a more effective choice for glioma gene therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873113

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  PAX6 suppresses growth of human glioblastoma cells.

Authors:  Yi-Hong Zhou; Xiaosong Wu; Fang Tan; Yue-Xi Shi; Tricia Glass; T J Liu; Kyle Wathen; Kenneth R Hess; Joy Gumin; Frederick Lang; W K Alfred Yung
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

2.  Correlation between 99mTc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines.

Authors:  Delphine Denoyer; Nathalie Perek; Nathalie Le Jeune; Jérôme Cornillon; Francis Dubois
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-23       Impact factor: 9.236

3.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Authors:  Marianela Candolfi; James F Curtin; W Stephen Nichols; Akm G Muhammad; Gwendalyn D King; G Elizabeth Pluhar; Elizabeth A McNiel; John R Ohlfest; Andrew B Freese; Peter F Moore; Jonathan Lerner; Pedro R Lowenstein; Maria G Castro
Journal:  J Neurooncol       Date:  2007-09-15       Impact factor: 4.130

4.  Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Authors:  Annick Desjardins; David A Reardon; James E Herndon; Jennifer Marcello; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman; James J Vredenburgh
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

5.  Hypoxic cell waves around necrotic cores in glioblastoma: a biomathematical model and its therapeutic implications.

Authors:  Alicia Martínez-González; Gabriel F Calvo; Luis A Pérez Romasanta; Víctor M Pérez-García
Journal:  Bull Math Biol       Date:  2012-11-14       Impact factor: 1.758

Review 6.  Novel technologies for antiangiogenic drug delivery in the brain.

Authors:  Ofra Benny; Pouya Pakneshan
Journal:  Cell Adh Migr       Date:  2009-04-06       Impact factor: 3.405

7.  VEGF immunopositivity related to malignancy degree, proliferative activity and angiogenesis in ENU-induced gliomas.

Authors:  S Bulnes; J V Lafuente
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

8.  NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.

Authors:  Ta-Jen Liu; Dimpy Koul; Tiffany LaFortune; Ningyi Tiao; Rui Jun Shen; Sauveur-Michel Maira; Carlos Garcia-Echevrria; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

9.  FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells.

Authors:  Yujian Zhang; Nu Zhang; Bingbing Dai; Mingguang Liu; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

10.  Current available therapies and future directions in the treatment of malignant gliomas.

Authors:  Annick Desjardins; David A Reardon; James J Vredenburgh
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.